Department of Life Sciences Ben-Gurion University of the Negev, P.O.B. 653, Beer-Sheva 84105, Israel.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi 110062, India; Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Buraydah Private Colleges, Al-Qassim 31717, Kingdom of Saudi Arabia.
Biosens Bioelectron. 2015 Nov 15;73:146-152. doi: 10.1016/j.bios.2015.05.051. Epub 2015 May 25.
A multiplexed MNPs-Abs based fluorescence spectroscopic system in analysis of serum biomarkers; CA-125, β2-M and ApoA1 for the early detection of ovarian cancer was first time proposed. The lowest detection limits measured in multiplexed setup were 0.26 U/mL, 0.55 ng/mL and 7.7 ng/mL respectively for CA-125, β2-M and ApoA1. A comparative real sample analysis of healthy normal (Control), benign and ovarian cancer patients with SPR has also been done to validate the process. Moreover CA-125 detection only confirms 50-60% of early stage disease. This multiplexed system achieved sensitivity and specificity up to 94% and 98% respectively to distinguish early stage ovarian cancer patients from healthy individuals.
首次提出了一种基于多重 MNPs-Abs 的荧光光谱系统，用于分析血清生物标志物；CA-125、β2-M 和 ApoA1 用于早期卵巢癌检测。在多重设置中测量的最低检测限分别为 CA-125、β2-M 和 ApoA1 的 0.26 U/mL、0.55 ng/mL 和 7.7 ng/mL。还使用 SPR 对健康正常（对照）、良性和卵巢癌患者的实际样本进行了比较分析，以验证该过程。此外，CA-125 检测仅能确认 50-60%的早期疾病。该多重系统在区分早期卵巢癌患者和健康个体方面的灵敏度和特异性分别高达 94%和 98%。
